New antiepileptic drugs: Comparison of key clinical trials

Epilepsia

Volumn 40, Issue 5, 1999, Pages 590-600

  Cramer, Joyce A ^a,b   Fisher, Robert ^c   Ben Menachem, Elinor ^d   French, Jacqueline ^e   Mattson, Richard H ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antiepileptic drugs; Clinical trials; Epilepsy; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN; LAMOTRIGINE; PLACEBO; TIAGABINE; TOPIRAMATE; VIGABATRIN;

ARTICLE; ATAXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG RESEARCH; EPILEPSY; GASTROINTESTINAL SYMPTOM; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VERTIGO;

EID: 0032890949     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb05561.x     Document Type: Article

References (43)

1. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313:145-51.
2. Mattson RH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for complex partial seizures and secondarily generalized tonic clonic seizures in adults. N Engl J Med 1992;327:765-71.
3. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. Br Med J 1996; 313:1169-74.
4. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new anti-epileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997;38:859-80.
5. Yusuf S. Meta-analysis of randomized trials: looking back and looking ahead. Controlled Clin Trials 1997;18:594-601.
6. Cramer JA, Mattson RH, Scheyer RD, French J. Meta-analysis of antiepileptic drug trials. Epilepsia 1998;39:233-4.
7. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536-42.
8. Bailar JC. The promise and problems of meta-analysis. N Engl J Med 337:559-60.
9. Chadwick DW. An overview of the efficacy and tolerability of new antiepileptic drugs. Epilepsia 1997;38(suppl 1):S59-62.
10. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 334:168-75.
11. Shorvon S, Stefan H. Overview of the safety of newer antiepileptic drugs. Epilepsia 1997;(suppl 1):S45-51.
12. Spilker B. Guide to clinical trials. New York: Raven Press, 1991:480.
13. Cramer JA, Smith DB, Mattson RH, Delgado-Escueta AV, Collins JF et al., and the VA Epilepsy Cooperative Study Group. A method of quantification for the evaluation of antiepileptic drug therapy. Neurology 1983;33(suppl 1):26-37.
14. Collins JF, Cramer JA, Mattson RH, and VA Epilepsy Cooperative Study Groups 118 and 264. Comparison of systemic and neurologic effects of standard antiepileptic drugs. Epilepsia 1997;38 (suppl 8):88-9.
15. Faught E, French J, Harden C, Glun B, Khan A, and the Postmarketing Antiepileptic Drug Survey Group (PADS). Adverse effects of topiramate: results from a large postmarketing survey. Epilepsia 1997;38(suppl 8):97-8.
16. French JA, Williams S, Morris G, Tatum W, Privitera M, Post-marketing Antiepileptic Drug Survey Group PADS). Post-marketing use of topiramate. Epilepsia 1997;38(suppl 8):96.
17. Gillam F, Kuzniecky R, Faught E, Black L, Carpenter G, Schrodt R. Patient-validated content of epilepsy-specific quality of life measurement. Epilepsia 1997;38:233-7.
18. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335:1114-7.
19. Anhut H, Ashman P, Fuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study; the International Gabapentin Study Group. Epilepsia 1994;35:795-801.
20. Sivenius J, Kalvainen R, Ylinen A, Riekkinen P. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991;32:539-42.
21. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebocontrolled, parallel-group study. Neurology 1993;43:2292-8.
22. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures: US Lamotrigine Protocol No. 5 Clinical Trial Group. Neurology 1993;43:2284-91.
23. Binnie D, Debets RM, Engelsman M, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add on therapy in intractable epilepsy. Epilepsy Res 1989;4:222-9.
24. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989;30:356-63.
25. Loiseau P, Yuen AW, Duche B, Menager T, Arne Bes MC. A randomized double-blind placebo-controlled cross-over add on trial of lamotrigine in patients with treatment resistant partial seizures. Epilepsy Res 1990;7:136-45.
26. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994;35:113-21.
27. Schapel GJ, Beran RG, Vajda FJ, et al. Double-blind, placebo-controlled, cross-over study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 1993;56:448-53.
28. Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add on treatment with lamotrigine in partial epilepsy. Epilepsy 1993;34:312-22.
29. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia 1995;6(suppl 6):S14-21. [101, 103, 106, 107, 109 studies].
30. Sachdeo RC, Leroy RF, Krauss GL, et al., for the Tiagabine Study Group. Tiagabine therapy for complex partial seizures: a dose frequency study. Arch Neurol 1997;54:595-601.
31. Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995;21:37-42.
32. Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol 1998;55:56-62.
33. Faught E, Wider BJ, Ramsay RE, et al. Topiramate controlled dose ranging trial refractory partial epilepsy using 200, 400, and 600 mg daily dosages. Neurology 1996;46:1684-90.
34. Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled, dose ranging study of topiramate in patients with partial epilepsy. Epilepsy Res 1996;25:217-24.
35. Ben-Menachem E. Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: the European experience. Epilepsia 1997;38(suppl 1):S28-30. [Y1, Y2, Y3 studies].
36. Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.
37. Privitera M, Fincham R, Renty J, et al. Topiramate controlled dose ranging trial in refractory partial epilepsy using 600, 800, and 1000 mg daily dosages. Neurology 1996;46:1678-83.
38. Ben-Menachem E, Henriksen O, Dam M, Schmidt D. Double-blind placebo-controlled trial of topiramate as add-on treatment in patients with refractory partial epilepsy. Epilepsia 1996;36:539-43.
39. Penry JK, Wilder BJ, Rajesh C, et al. Multicenter dose-response study of vigabatrin in adults with focal (partial) epilepsy [Abstract]. Epilepsia 1993;34(suppl 6):67.
40. Beran RG, Berkovic SF, Buchanan N, et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure 1996;5:259-65.
41. French JA, Mosier M, Walker S, Somerville K, Sussman N, and the Vigabatrin Protocol 024 Investigative Cohort. A double-blind, placebo-controlled study of vigabatrin 3 g/day in patients with uncontrolled partial seizures. Neurology 1996;46:54-61.
42. Grunewald RA, Thompson PJ, Corcoran R, Corden Z, Jackson GD, Duncan JS. Effects of vigabatrin on partial seizures and cognitive function. J Neurol Neurosurg Psychiatry 1994;57:1057-63.
43. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276:637-9.